Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IDEXX LABORATORIES INC /DE Director's Dealing 2011

Feb 28, 2011

30016_dirs_2011-02-28_13990810-a4df-4652-999f-bbc228e4cb58.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2011-02-25

Reporting Person: DEADY CONAN R (Corp VP, General Counsel & Sec)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-02-25 Common Stock M 23054 $17.1350 Acquired 42401 Direct
2011-02-25 Common Stock M 18072 $25.45 Acquired 60473 Direct
2011-02-25 Common Stock M 9472 $38.3350 Acquired 69945 Direct
2011-02-25 Common Stock S 43484 $77.048 Disposed 26461 Direct
2011-02-25 Common Stock S 7114 $75.8462 Disposed 19347 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-02-25 Non-Qualified Stock Option (right to buy) $17.1350 M 23054 Disposed 2013-02-06 Common Stock (23054) Direct
2011-02-25 Non-Qualified Stock Option (right to buy) $25.45 M 18072 Disposed 2014-02-04 Common Stock (18072) Direct
2011-02-25 Non-Qualified Stock Option (right to buy) $38.3350 M 9472 Disposed 2013-02-13 Common Stock (9472) Direct

Footnotes

F1: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.33 to $76.57, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2 to this Form 4.

F2: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $76.31 to $75.80, inclusive.

F3: Grant of options to buy shares of common stock becomes exercisable as to 6,400 shares on 02/06/2004, 02/06/2005, 02/06/2006, 02/06/2007, and the remaining 564 shares on 02/06/2008.

F4: Grant of options to buy shares of common stock becomes exercisable as to 4,400 shares on 02/05/2005, 02/05/2006, 02/05/2007, 02/05/2008, and the remaining 472 shares on 02/05/2009.

F5: Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date (02/14/2007) of the date of grant.